Latest Breast Cancer News | Breast Tumor Research Articles

Breast Cancer News


Breast Cancer News

Tucatinib Gets Priority Review for Locally Advanced or Metastatic HER2-Positive Breast Cancer

The FDA has accepted for Priority Review the New Drug Application (NDA) for tucatinib (Seattle Genetics), in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant or metastatic setting.

Emerging Therapeutic Approaches for Metastatic HER2-Positive Breast Cancer

Content was developed by PRI Healthcare Solutions, a division of Haymarket Media, Inc. Advertising support received from Seattle Genetics, Inc. Seattle Genetics, Inc. did not influence or provide oversight over content.   In this video, breast medical oncologist, Carey Anders, MD, medical director of the Duke Center for Brain and Spine Metastasis at the Duke…
Next post in Breast Cancer News